TABLE I 1-NAPHTHYLALKYLCARBAMATES



. A

Compd	R	\mathbf{R}_{1}	$\sum_{n=1}^{\infty} \mathbf{N}(\mathbf{C}[\mathbf{H}])_{n}$	Reflax time, la	Yiebl, *5"	Bp (mm), ^s C	Formula ³
1	$i-C_3H_7$	$\mathrm{NHCO_2Et}$	$(CH_3)_2N(CH_2)_2$	8	65.6	С	$C_{21}H_{20}N_2O_2$
2	i-C; H ₇	$\rm NHCO_2Et$	d	8	78.4	с	$C_{24}H_{74}N_2O_2$
3	Н	$\rm CH_2 NHCO_2 Et$	$(CH_{*})_{2}N(CH_{2})_{2}$	3	65.4	190-192(0.3)	$\mathrm{G}_{19}\mathrm{H}_{26}\mathrm{N}_{2}\mathrm{O}_{2}$
4	CH.	CH_2NHCO_2Et	$(CH_{5})_{2}N(CH_{2})_{2}$	8	56.2	С	$C_{20}H_{28}N_2O_2$
5	$i-C_3H_7$	$\rm CH_2 NHCO_2 Et$	$(CH_3)_2N(CH_2)_2$	5	77	c	$C_{22}H_{32}N_2O_2$
6	sec -C4H $_9$	CH_2NHCO_2Et	$(CH_{\delta})_{2}N(CH_{2})_{2}$	5	39.2	c	$C_{2*}H_{34}N_2O_2$
7	$(CH_3)_2 N (CH_2)_2$	CH_2NHCO_2Et	$(CH_3)_2 N (CH_2)_2$	8	74	c	$\mathrm{C}_{25}\mathrm{H}_{85}\mathrm{N}_{3}\mathrm{O}_{2}$
8	$i-C_3H_7$	CH_2NHCO_2Et	$\mathrm{CH}_{\mathrm{b}}(\mathrm{C}_{2}\mathrm{H}_{5})\mathrm{N}(\mathrm{CH}_{2})_{2}$	5	82.2	c	$\mathrm{C}_{25}\mathrm{H}_{34}\mathrm{N}_{2}\mathrm{O}_{2}$
9	i-C ₃ H,	CH ₂ NHCO ₂ Et	$(C_2H_5)_2N(CH_2)_2$	5	82	c	$\mathrm{C}_{24}\mathrm{H}_{36}\mathrm{N}_{2}\mathrm{O}_{2}$
10	sec-C ₄ H ₂	CH ₂ NHCO ₂ Et	$(G_2H_5)_2N(CH_2)_2$	5	60.8	c:	$C_{25}H_{28}N_2O_2$
11	$i-C_3H_7$	CH₂NHCO₂Et	$((-C_3H_5)_2N(CH_2)_2$	5	60	c	$C_{26}II_{40}N_2O_2$
12	CH_3	CH ₂ NHCO ₂ Et	e	8	58.3	c	$C_{22}H_{50}N_2O_2$
13	$i-C_{3}H_{7}$	CH ₂ NHCO₂Et	ϵ	5	63.4	c	$\mathrm{C}_{24}\mathrm{H}_{34}\mathrm{N}_{2}\mathrm{O}_{2}$
14	sec-C4H9	CH₂NHCO₂Et	ŕ	.,	48.8	c	$C_{25}H_{36}N_2O_2$
15	ϵ	CH₂NHCO₂Et	ť	8	41	e	$C_{27}H_{29}N_3O_2$
16	Н	CH ₂ NHCO ₂ Et	d	3	81.5	215 - 218 (0.5)	$C_{22}H_{30}N_2O_2$
17	CH_3	CH ₂ NHCO ₂ Et	đ	ō	67	c	$C_{23}H_{32}N_2O_2$
18	$i-C_{4}H_{7}$	CH_2NHCO_2Et	d	ō	81.4	r	$C_{25}H_{36}N_2O_2$
19	d	$\mathrm{CH}_{2}\mathrm{NHCO}_{2}\mathrm{Et}$	d	5	80	с	$\mathrm{C}_{29}\mathrm{H}_{43}\mathrm{N}_{3}\mathrm{O}_{2}$
20	CH₃	CH ₂ NHCO ₂ Et	f	5	88	·,	$\mathrm{C}_{22}\mathrm{H}_{30}\mathrm{N}_{2}\mathrm{O}_{3}$
21	$i-C_{3}H_{7}$	$\rm CH_2 NHCO_2 Et$	ſ	5	55.7	c	$\mathrm{C}_{24}\mathrm{H}_{34}\mathrm{N}_{2}\mathrm{O}_{3}$
22	f	CH_2NHCO_2Et	f	10	66.4	c	$C_{27}H_{39}N_3O_4$
23	CH_8	CH_2NHCO_2Et	$(CH_3)_2N(CH_2)_4$	5	80.2	c	$\mathrm{C}_{21}\mathrm{H}_{50}\mathrm{N}_{2}\mathrm{O}_{2}$
24	sec-C4H4	CH ₂ NHCO ₂ Et	$(\mathrm{CH}_3)_2 \mathbf{N} (\mathrm{CH}_2)_3$	3	43.5	C	$\mathrm{C}_{24}\mathrm{H}_{36}\mathrm{N}_{2}\mathrm{O}_{2}$
25	<i>i</i> -C₃H ,	CH ₂ NHCO ₂ Et	9	3	66.6	c	$\mathrm{C}_{26}\mathrm{H}_{38}\mathrm{N}_2\mathrm{O}_2$
26	sec-C4H9	CH ₂ NHCO ₂ Et	h	-1	92.7	Ċ	$C_{26}H_{*8}N_2O_2$
27	sec-C4H9	CH ₂ NHCO ₂ Et	$(CH_2)_2 N(CH_2)_4$	5	56.ti	(*	$C_{25}H_{35}N_2O_2$
28	i-C.H.	CH ₂ NHCO ₂ Et	i	.5	80.4	С	${ m C_{27} H_{40} N_2 O_2}$
29	$i-C_3H_7$	CH_2NHCO_2Et	j	-1	76.2	с	$C_{26}H_{38}N_2O_3$

^a Crude product. ^b All compounds were analyzed for C, H, N and the analytical results were within $\pm 0.4\%$ of the theoretical values. ^c Waxy product. ^d 2-Piperidinoethyl. ^e 2-(1-Pyrrolidinyl)ethyl. ^f 2-Morpholinoethyl. ^g 3-Piperidinopropyl. ^b 3-Morpholinopropyl. 4-Piperidinobutyl. 4-Morpholinobutyl.

29 prolonged pentobarbital sleeping time at 40 mg/kg ip. However, this effect had only slight pharmacological significance. Compounds 12 and 20 displayed some activity in the antireserpine test but were less active than imipramine. In none of the other assays did the compounds exert any noteworthy activity.

Experimental Section⁸

The intermediate amines were prepared as previously described.1

Ethyl 1-Naphthylalkylcarbamates .--- A solution of the appropriate amine (0.1 mol) and ClCO₂Et (0.15 mol) in anhydrous C_6H_6 (190 ml) was refluxed in the presence of K_2CO_3 (0.15 mol). The reaction mixture was extracted with 10% HCl, the acid solution made alkaline with 10% NaOH, and the precipitate which formed extracted (Et₂O). The ethereal solution was washed (H2O) until neutral, dried (Na2SO4), and evaporated to dryness to give an oily or waxy product.

Acknowledgments.—The authors wish to thank Dr. R. Perego for performing microanalyses, Mr. G. Bietti

for assistance in preparing the compounds, and Miss L. Tomasi and Miss C. Bacci for carrying out the pharmacological tests.

Synthesis and Endocrine Activity of

Some 3-Aza-A-homopregnenes

ARVIN P. SHROFF

Division of Organic Chemistry, Ortho Research Foundation, Raritan, New Jersey 08869

Received March 9, 1970

The nucleotide, cyclic 3',5'-adenosine monophosphate (cyclic AMP), is a naturally occurring intracellular constituent that has been shown to influence a wide variety of physiological functions.¹⁻³ Hormones and

⁽⁸⁾ Boiling points are uncorrected,

⁽¹⁾ M. A. Rizack, J. Biol. Chem., 239, 392 (1964).

⁽²⁾ E. W. Sutherland and T. W. Rall, *Pharmacol. Rev.*, 12, 265 (1960).
(3) S. Tarui, K. Nanaka, Y. Ikura, and K. Shima, *Biochem. Biophys* Res. Commun., 13, 329 (1963).

neurohormones increase the tissue concentration of cyclic AMP at target cells, thus indicating⁴ that this cyclic nucleotide may be responsible in mediating the response of the hormones. Haynes and Berthet⁵ have shown cyclic AMP to be a mediator for the action of ACTH on steroidogenis in the adrenal cortex. Similarly, Marsch and Savard⁶ have demonstrated that cyclic AMP acts as a mediator of the stimulatory action of LH on steroidogenesis.

We became interested in exploring these observations from a synthetic point of view and chose 17α -acetoxyprogesterone and 6α -methyl- 17α -acetoxyprogesterone for our molecular modifications. Conversion of the 3-ketone into the oxime followed by Beckmann rearrangement to an A-homo lactam (Scheme I) would impart a certain amount of basicity to the steroid molecule which could conceivably bind to 3',5'-cyclic nucleotide phosphodiesterase, the enzyme that catalyzes the hydrolysis of cyclic AMP to 5'-AMP. Bases such as theophylline and caffeine have been shown⁷ to inhibit 3',5'-cyclic nucleotide phosphodiesterase thus building up the intracellular concentration of cyclic AMP for physiological activity.

The oximes and their Beckmann rearranged products were synthesized according to the procedure outlined in the Experimental Section. The spectral data confirm the structural assignment. The physical properties of these compounds are summarized in Tables I and II.



^a All compounds showed uv absorption at 240 m μ . ^b A, acetone; M, methanol; W, water. ^c Acceptable C, H, N values were obtained for all compounds.

The progestational response of these compounds was determined by the Clauberg test⁸ and the endometrial response was scored according to the index of McPhail.⁹ The individual responses are tabulated in Table III. Compounds **4** and **9** were the most potent compounds in the series. On a milligram basis, **4** was about 10 times as potent as **1** which lacks the 6α -Me group. Similarly, **9** was also about 10 times as potent as the corresponding lactam **7** without the 6α -Me group. Interestingly, the

- (6) J. M. Marsch and K. Savard, Steroids, 8, 133 (1966).
 (7) R. W. Butcher and E. W. Sutherland, J. Biol. Chem., 237, 1244 (1962).
- (7) R. W. Butcher and E. W. Sutherland, J. Biol. Chem., 237, 1244 (1962).
 (8) C. Clauberg, Zentralbl. Gynaekol., 54, 2757 (1930).
- (9) M. K. McPhail, J. Physiol. (London), 83, 145 (1935).



^a All compounds showed uv absorption around 220 mµ. ^b A, acetone; EA, ethyl acetate; E, ether; H, hexane. ^c Acceptable C, H, N values were obtained for all compounds.

	TABLE III	
Progestati	ONAL RESPONSE OF RA	BBIT UTERUS
Compd no.	Dose, mg/kg	McPhail index
1	5.0	2.6
2	ō.0	1.1
3	5.0	0.3
4	0.5	3.1
5	5.0	3.3
6	5.0	2.7
7	5.0	2.5
8	5.0	0
9	0.5	3.0
10	5.0	1.2

oxime 4 and its corresponding lactam 9 are equally potent and marks the first time, to our knowledge, that an azasteroid 9 has imparted such a potent endocrine activity. Introduction of a long-chain fatty ester at C-17 in both series (6H and 6α -Me) decreases the activity precipitously.

No data are available at present on the mode of action of these types of steroids but it is possible, judging from their progestational response, that these compounds act at the 3',5'-cyclic nucleotide phosphodiesterase level thus inducing a sufficient build-up of cyclic AMP for the observed response (Scheme II). The necessity of 6α -Me group to enhance the progestational response suggests the β face interaction with

⁽⁴⁾ R. C. Haynes, Jr., E. W. Sutherland, and T. W. Rall, Recent Progr. Horm. Res., 16, $121\frac{1}{4}(1960)$.

⁽⁵⁾ R. C. Haynes, Jr. and L. Berthet, J. Biol. Chem., 225, 115 (1957).



phosphodiesterase. Also, both **4** and **9** must have common binding sites.

Experimental Section

All melting points were taken on a Fisher–Johns melting point apparatus and are uncorrected. The uv and ir data were obtained on a Cary Model 11 and Beckmann IR-5 spectrophotometers, respectively. The unrespectra were determined on a Varian A-60 spectrometer in CDCl₃ using TMS as an internal standard (0 ppm). All parts per million values are the center of the signals. Microanalyses were performed by Midwest Microlab, Inc., Indianapolis, Ind. Where analyses are indicated only by symbols of the elements. (Tables I and II), analytical results obtained for those elements were within $\pm 0.4e_{0}^{c}$ of the theoretical value.

General Method. Oximes. 3-Oximino-17 α -acetoxypregn-4ene-3,20-dione (1)....A solution containing 1.0 g of 17 α -acetoxyprogesterone, 250 mg of HONH₃ $^{+}$ ·Cl⁻, and 5 ml of C₅H₅N was heated on a stean bath for 1.5 hr. The mixture was poured into a large amount of ice-water and the crude oxime thus precipitated was collected by filtration. Recrystallization from MeOH gave 1.0 g of 1: mp 240–241°; [α]p +97.6°; λ_{max}^{Khr} 3.02, 5.75, 5.82 6.1 μ ; λ_{max}^{Khr} 240 m μ ; mmr (CDCl₃) 0.70 ppm (C-18), 1.11 (C-19), 2.06 (C-21), 2.12 (C-17 OAc), 5.89 (C-4 anti), and 6.6 (C-4 Syn).

General Method. Beckmann Rearrangements. 3-Aza-17 α acetoxy-A-homo-4a-pregnene-4,20-dione (7).--To a solution containing 4.0 g of 1 in 30 ml of purified dioxane was added 5 ml of SOCl₂. The mixture was stirred at room temperature for 1.5 hr and poured into a large amount of icc-water. The excess acid was neutralized with NaHCO₃ and the solution was extracted with CH₂Cl₂. The organic layer was washed (H₂O), dried (Na₂-SO₄), and filtered. The filtrate was evaporated to give a brown oil which could be recrystallized from acetone-hexane to give 1.4 g of 8: mp 274-277°: [α] +15.9°: $\lambda_{max}^{60\mu}$ 3.1, 5.75, 5.80 6.05 μ : λ_{max}^{Ecoff} 221 m μ ; mmr (CDCl₃) 0.67 ppm (C-18), 1.15 (C-19), 2.04 (C-21), and 2.09 (C-17 OAc).

Acknowledgment.—I wish to thank Dr. I. Scheer for his encouragement and interest, and Dr. R. P. Blye of our Division of Pharmacology for the biological data.

Preparation of 6-Acetamino-16-methylene-17α-hydroxy-4,6-pregnadiene-3,20-dione 17-Acetate

G. TEUTSCH,¹ E. L. SHAPIRO, AND H. L. HERZOG

Natural Products Research Department, Schering Corpocation, Bloomfield, New Jerseg 07003

Received February 27, 1970

Much attention has been devoted in recent years to 6-substituted 6-dehydroprogesterone analogs, among which 6-chloro-17 α -hydroxy-4,6-pregnadiene-3,20dione 17-acetate (2) (chlormadinone), has found wide use as the progestational factor in contraceptives and has been clinically investigated for independent antifertility action.² Following the discovery of the large progestagenic potentiating effect of a 16-methylene substituent,³ active interest has developed in this new

(3) E. Shapiro, T. Legatt, L. Weber, M. Steinberg, A. Watnick, M. Eisler, M. Gilmore Hennessey, C. T. Coniglio, W. Charney, and E. P. Oliveto, J. Med. Chem., 5, 975 (1962), and ref therein.



class of compounds, both for their potential progestagenic⁴ and antiandrogenic⁵ activities.

In the present communication we wish to report briefly on the synthesis, as well as progestational and antiandrogenic evaluation, of the 6-acetamino analog 1b.

The synthetic procedure used, in essence, was the one outlined earlier by Brückner and coworkers⁶ for the synthesis of **2**, and subsequently modified for the synthesis of the 16-methylene homolog **1a**, by Shapiro and coworkers.^{7a} It involved the opening of a 6α , 7α -epoxide with a nucleophile, followed by the elimination of the 7α function with *p*-TSA^{7b} to introduce the 6,7 double bond. The use of MeCN as a nucleophile for the acidcatalyzed opening of epoxides to acetamino alcohols has been reported recently by Julia and coworkers,⁸ who applied their finding to the opening of 5α , 6α -, 5β , 6β -, and

(8) (a) S. Julia and G. Bourgery, C. R. Acad. Sci., Ser. C., 264, 333 (1967);
 (b) S. Julia, G. Bourgery, and J. J. Frankel, *ibid.*, 267, 1861 (1968).

⁽¹⁾ Post-Doctoral Fellow, 1968 and 1969.

⁽²⁾ For a review in this field see E. Diczfalusy, Amer. J. Obst. Gynecol., 100, 136 (1968) and ref therein.

^{(4) (}a) H. J. Mannhardt, F. v. Werder, K. H. Bork, H. Metz, and K. Brückner, Tetrahedron Lett., 21 (1960); (b) K. H. Bork, K. Brückner, L. Jahn, H. J. Mannhardt, and F. v. Werder, German Patent 1,156,407 (1963);
(c) V. Petrow, U.S. Patent 3,117,966 (1964); (d) K. Sybora nd R. Mazae. Collect. Czech. Chem. Commun., **31**, 2768 (1966); (e) Z. Cekan, M. Seda, J. Mikulaskova, and K. Syhora, Steroids, **8**, 205 (1966); (f) F. P. Oliveto, R. Rausser, and E. B. Hersiberg, U.S. Patent 3,312,692 (1967); (g) D. Burn, M. Lester, and V. Petrow, U.S. Patent 3,375,167 (1968).
(5) (a) S. Rocky and R. Neri, Fed. Proc., **37**, 624 (1968); (b) C. Casmer,

 ^{(5) (}a) S. Rocky and R. Neri, Fed. Proc., 27, 624 (1968); (b) C. Casmer,
 F. Fielder, and R. Neri, Northeast Conference of Comparative Endocrinology, Boston University, Boston, Mass., 1968.

⁽⁶⁾ K. Brückner, B. Hampel, and U. Johnsen, *Chem. Ber.*, 94, 1225 (1961).
(7) (a) E. L. Shapiro, H. L. Herzog, and L. Weber, U.S. Patent 3,493,588 (Feb. 3, 1970);
(b) The acid medium utilized in U.S. Patent 3,493,588 is HCl-CHCls.